Back to results
US 2013/0172534 A1Published application
Antibodies to ox-2/cd200 and uses thereof
AssigneeAlexion Pharmaceuticals, Inc.
InventorsKatherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
Life of this patent
Estimating the term…
Abstract
This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
Claims31
1-126. (canceled)
An isolated anti-CD200 antibody that:
- (i) inhibits the interaction between CD200 and CD200R;
- and
- (ii) comprises a variant Fc constant region that has ADCC activity or CDC activity equal to or less than the ADCC activity or CDC activity the anti-CD200 antibody would have if it had a G2/G4 Fc constant region consisting of amino acid residues 137-462 of SEQ ID NO:13.
An isolated anti-CD200 antibody that:
- (i) inhibits the interaction between CD200 and CD200R;
- and
- (ii) comprises a variant Fc constant region that exhibits decreased effector function relative to the effector function of the native Fc constant region from which the variant Fc constant region was engineered.
An isolated anti-CD200 antibody comprising a G2/G4 constant region, wherein the anti-CD200 antibody inhibits the interaction between CD200 and CD200R.
Dependencies are inferred from the claim text.